* Intra-Cellular Therapies Inc ITCI.OQ reported a
quarterly
adjusted loss of 16 cents per share for the quarter ended
December 31, higher than the same quarter last year, when the
company reported EPS of -30 cents. The mean expectation of
thirteen analysts for the quarter was for a loss of 11 cents per
share. Wall Street expected results to range from -40 cents
to 22 cents per share.
* Revenue rose 50.8% to $199.22 million from a year ago;
analysts
expected $193.40 million.
* Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 16 cents.
* The company reported a quarterly loss of $16.89 million.
* Intra-Cellular Therapies Inc shares had risen by 53.9%
this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 6.2%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"
Wall Street's median 12-month price target for Intra-Cellular
Therapies Inc is $132.00
This summary was machine generated from LSEG data February 21 at
02:08 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2024 -0.11 -0.16 Missed
Sep. 30 2024 -0.20 -0.25 Missed
Jun. 30 2024 -0.19 -0.16 Beat
Mar. 31 2024 -0.32 -0.16 Beat